Suggested remit: To appraise the clinical and cost effectiveness of abaloparatide within its marketing authorisation for treating osteoporosis in postmenopausal women.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA Standard
ID number 882

Provisional Schedule

Committee meeting: 1 14 May 2024
Committee meeting: 2 09 July 2024

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors Theramex (abaloparatide)
Others Department of Health and Social Care
  Health Technology Wales (HTW)
  NHS England
Patient carer groups Royal Osteoporosis Society
Professional groups Royal College of Physicians
  Royal College of Radiologists
Assessment group Accord Healthcare (alendronic acid, ibandronic acid, teriparatide) (confidentiality agreement not signed, not participating)
  Accord-UK (raloxifene, risedronate sodium) (confidentiality agreement not signed, not participating)
  Amgen (denosumab) (confidentiality agreement not signed, not participating)
  Aristo Pharma (risedronate sodium, strontium ranelate) (confidentiality agreement not signed, not participating)
  Aspire Pharma (ibandronic acid, raloxifene, risedronate sodium) (confidentiality agreement not signed, not participating)
  Atnahs Pharma (ibandronic acid) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma - Milpharm (alendronic acid, risedronate sodium) (confidentiality agreement not signed, not participating)
  Dr. Reddy's Laboratories (zoledronic acid) (confidentiality agreement not signed, not participating)
  Eli Lilly (teriparatide) (confidentiality agreement not signed, not participating)
  Gedeon Richter (teriparatide) (confidentiality agreement not signed, not participating)
  Internis Pharmaceuticals (alendronic acid) (confidentiality agreement not signed, not participating)
  Mylan (ibandronic acid)
  Novartis (zoledronic acid)
  Organon Pharma (alendronic acid)
  Ranbaxy (UK) Limited a Sun Pharmaceutical Company (zoledronic acid) (confidentiality agreement not signed, not participating)
  Rosemont (alendronic acid) (confidentiality agreement not signed, not participating)
  Sandoz (risedronate sodium, ibandronic acid) (confidentiality agreement not signed, not participating)
  Seacross Pharmaceuticals (zoledronic acid) (confidentiality agreement not signed, not participating)
  Teva UK (teriparatide) (confidentiality agreement not signed, not participating)
  Thornton & Ross (teriparatide) (confidentiality agreement not signed, not participating)
  UCB Pharma (romosozumab) (confidentiality agreement not signed, not participating)
  Vygoris (raloxifene) (confidentiality agreement not signed, not participating)
  Zentiva (ibandronic acid) (confidentiality agreement not signed, not participating)
  School of Health and Related Research (ScHARR)
Associated public health groups None
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups National Institute of Health Research

Timeline

Key events during the development of the guidance:

Date Update
27 July 2023 Invitation to participate
23 March 2023 Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Abaloparatide for treating osteoporosis in postmenopausal women have been revised. It is anticipated that the appraisal will begin in mid-July 2023 when we will write to you about how you can get involved.
25 January 2023 - 22 February 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 882
25 January 2023 In progress. Scoping commencing
17 June 2016 Suspended. For information abaloparatide will be appraised alongside raloxifene, teriparatide, denosumab and strontium ranelate [ID901] as a Multiple Technology Appraisal (MTA). Further details regarding the timings of this MTA will be available in due course.
17 June 2016 Draft scope documents

For further information on our processes and methods, please see our CHTE processes and methods manual